Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Emmaus Life Sciences Inc (EMMA)

Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Emmaus Life Sciences Reports Annual Financial Results Business Wire - Mon Mar 30, 9:00PM CDT

Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Announces Strategic Transaction Business Wire - Tue Dec 30, 2025

Enters into North American License and Exclusive Distribution Agreement

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Reports Quarterly Financial Results PR Newswire - Fri Nov 14, 2025

TORRANCE, Calif. , Nov. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Reports Quarterly Financial Results PR Newswire - Thu Aug 14, 2025

TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Reports Management Changes PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Reports Q2 2023 Financial Results PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman PR Newswire - Thu Jul 13, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update PR Newswire - Mon May 15, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0091 (-9.90%)
Emmaus Life Sciences Provides Interim Shipment Data PR Newswire - Mon Apr 3, 2023

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...

EMMA : 0.0091 (-9.90%)

Barchart Exclusives

This Dividend Stock Keeps Hitting It Out of the Park: Should You Buy? Barchart - Wed Apr 22, 6:30PM CDT
Citigroup's financial performance has been impressive over the last couple of years as its transformation under CEO Jane Fraser is bearing fruit. Is the stock a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.